🔎 Trials Near Me

Home › Ischemic Stroke › NCT06289985

StrokeNet Thrombectomy Endovascular Platform

Recruiting

STEP: StrokeNet Thrombectomy Endovascular Platform

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
STEP PLATFORM INCLUSION CRITERIA:

1. Suspected diagnosis acute ischemic stroke
2. Likely causative intracranial large or medium vessel occlusion

STEP PLATFORM EXCLUSION CRITERIA:

1. Proven contraindication to endovascular thrombectomy
2. Prisoners/incarcerated

DOMAIN-SPECIFIC ELIGIBILITY CRITERIA:

Each domain may have additional eligibility criteria.

STEP EVT INDICATION EXPANSION DOMAIN INCLUSION CRITERIA:

1\. Age 18 years or older 2. Pre-stroke modified Rankin Scale score 0-2 3. Presentation to enrolling hospital within 24 hours of last known well/stroke onset 4. Able to initiate arterial puncture within 2 hours from qualifying CTA/MRA or CTP/MRP imaging

\*CT/MR and qualifying CTA/MRA or CTP/MRP should be repeated if more than 120 minutes have elapsed since the imaging and randomization has not been performed. The exception is for LVO Mild deficit/Low NIHSS 0-5 for which imaging would only need to be repeated if there has been significant improvement in the NIHSS prior to randomization.

5\. Has one of the following presentations:

1. LVO patients with mild deficits/low NIHSS (must have both):

   1. Mild presenting neurologic deficits - NIHSS 0-5 (Must have some focal neurological deficit attributable to the target occlusion if NIHSS 0)
   2. Complete occlusion of the intracranial Internal Carotid Artery (ICA) or M1 Middle Cerebral Artery (MCA)
2. Medium/Distal Vessel Occlusion:

   1. Visualized complete occlusion or perfusion deficit (Tmax \> 4s) supportive of a cortical branch occlusion in one of the following vessels:

      i) Non-dominant/Co-dominant M2 (defined as serving \< 50% of entire overall MCA territory) ii) M3
   2. If symptom onset is \> 6h, the core must be less than 50% of the territory supplied by the occluded vessel as evident by either:

      i) Hypodensity and loss of grey-white border on NCCT or ii)ADC \<620 mm2/s on diffusion MRI or rCBF\<30% on CTP
   3. NIHSS \> =8

STEP EVT INDICATION EXPANSION DOMAIN EXCLUSION CRITERIA:

1. Clinical

   1. Presumed septic embolus; suspicion of bacterial endocarditis
   2. Seizure at stroke onset or between onset and enrollment
   3. Known anaphylactic reaction to contrast material that precludes endovascular reperfusion therapy
   4. Intracranial occlusion suspected to be chronic, based on history and/or imaging
   5. Intracranial dissection, based on history and/or imaging
   6. Cerebral vasculitis, based on history and/or imaging
   7. Known pregnancy
   8. Known pre-existing medical, neurological or psychiatric disease that would confound the neurological or functional evaluations
   9. Known serious, advanced, or terminal illness or life expectancy less than 6 months in the investigator judgment
   10. Known or high suspicion for underlying intracranial atherosclerotic disease (ICAD)
2. Laboratory

   a. Known platelet count \<100,000/uL
3. Imaging

   1. CT ASPECT score \<6 (MRI ASPECT score \<7)
   2. Unfavorable vascular anatomy that limits access to the occluded artery precluding endovascular reperfusion therapy.
   3. Acute occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation)
   4. Tandem occlusions
   5. Significant mass effect with midline shift (\>5mm)
   6. Evidence of intra-cranial tumor (except small meningioma defined as (1) \<=3 cm, (2) asymptomatic) as confirmed on CT/MRI)
   7. Evidence of acute intracranial hemorrhage

About the study

STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).

What is being tested

Sponsor: Medical University of South Carolina · Participants: 1,600 · Started: Jan 31, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06289985

Locations in the U.S.

AlabamaUniversity of Alabama Hospital, Birmingham
CaliforniaUCSD Health La Jolla, La Jolla
Kaiser Permanente Los Angeles Medical Center, Los Angeles
Ronald Reagan UCLA Medical Center, Los Angeles
UCSD Medical Center - Hillcrest Hospital, San Diego
Stanford University Medical Center, Stanford
ConnecticutHartford Hospital, Hartford
Yale New Haven Hospital, New Haven
FloridaJackson Memorial Hospital, Miami
Tampa General Hospital, Tampa
GeorgiaGrady Memorial Hospital, Atlanta
IllinoisUniversity of Chicago Medical Center, Chicago
IowaUniversity of Iowa Hospitals & Clinics, Iowa City
MassachusettsBoston Medical Center, Boston
Brigham and Women's Hospital, Boston
MinnesotaM Health Fairview Southdale Hospital, Edina
M Health Fairview University of Minnesota Medical Center, Minneapolis
MissouriBarnes Jewish Hospital, St Louis
New JerseyCooper University Hospital, Camden
New YorkNYU Langone Hospital, Brooklyn
Buffalo General Medical Center, Buffalo
The Mount Sinai Hospital, New York
Stony Brook University Hospital, Stony Brook
Montefiore Medical Center, The Bronx
North CarolinaCarolinas Medical Center, Charlotte
Wake Forest Baptist Medical Center, Winston-Salem
OhioUniversity of Cincinnati Medical Center, Cincinnati
Cleveland Clinic, Cleveland
UH Cleveland Medical Center, Cleveland
OSU Wexner Medical Center, Columbus
PennsylvaniaHospital of the University of Pennsylvania, Philadelphia
UPMC Mercy Hospital, Pittsburgh
UPMC Presbyterian Hospital, Pittsburgh
Rhode IslandRhode Island Hospital, Providence
South CarolinaMedical University of South Carolina University Hospital, Charleston
TexasMemorial Hermann Texas Medical Center, Houston
Medical City Plano, Plano
University of Texas Health Science Center, San Antonio
UtahUniversity of Utah Healthcare, Salt Lake City
VirginiaUVA Medical Center, Charlottesville
WashingtonHarborview Medical Center, Seattle

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.